NCT02045212View on ClinicalTrials.gov

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions
Non-arteritic Ischemic Optic NeuropathyOptic Nerve Injuries
Interventions
DRUG

RPh201

SC injection twice a week during 13/26 weeks

DRUG

Placebo

SC injection twice a week during 13/26 weeks

Trial Locations (1)

Unknown

Ophthalmology Department, Western Galilee-Nahariya Medical Center, Nahariya

All Listed Sponsors
lead

Regenera Pharma Ltd

INDUSTRY

NCT02045212 - Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). | Biotech Hunter | Biotech Hunter